POZEN Inc.  

(Public, NASDAQ:POZN)   Watch this stock  
Find more results for POZN
7.68
+0.07 (0.92%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.60 - 7.97
52 week 5.96 - 9.73
Open 7.61
Vol / Avg. 173,614.00/217,631.00
Mkt cap 245.40M
P/E 12.90
Div/yield 1.75
EPS 0.60
Shares 32.25M
Beta 2.10
Inst. own 57%
May 6, 2015
Q1 2015 POZEN Inc Earnings Release (Estimated) Add to calendar
Mar 9, 2015
Q4 2014 Pozen Inc Earnings Call - Webcast
Mar 9, 2015
Q4 2014 Pozen Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 70.99% 60.74%
Operating margin 68.52% 51.17%
EBITD margin - 51.23%
Return on average assets 58.95% 45.87%
Return on average equity 66.60% 60.98%
Employees 12 -
CDP Score - -

Address

1414 Raleigh Rd Ste 400
CHAPEL HILL, NC 27517-8834
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

POZEN Inc. (POZEN) is a pharmaceutical company focused on transforming medicine. The Company had developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet is the brand name for the product combining sumatriptan 85 milligram, formulated with RT Technology and naproxen sodium 500 milligram in a single tablet designed for the acute treatment of migraine. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. VIMOVO is known for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

Officers and directors

John R. Plachetka Pharm.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
William L. Hodges CPA Chief Financial Officer, Senior Vice President - Finance and Administration
Age: 60
Bio & Compensation  - Reuters
Gilda M. Thomas J.D. Senior Vice President, General Counsel
Age: 60
Bio & Compensation  - Reuters
Dennis L. McNamara Senior Vice President, Chief Business Officer
Age: 42
Bio & Compensation  - Reuters
John E. Barnhardt CPA Vice President - Finance and Administration
Age: 65
Bio & Compensation  - Reuters
John G. Fort M.D. Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Kenneth B. Lee Jr., MBA Lead Independent Director
Bio & Compensation  - Reuters
Neal F. Fowler Independent Director
Age: 52
Bio & Compensation  - Reuters
Arthur S. Kirsch Independent Director
Age: 62
Bio & Compensation  - Reuters
Seth A. Rudnick M.D. Independent Director
Bio & Compensation  - Reuters